Cargando…

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma

SIMPLE SUMMARY: The mechanism of resistance to multikinase inhibitors in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the responsible miRNAs and target genes...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirao, Akihiro, Sato, Yasushi, Tanaka, Hironori, Nishida, Kensei, Tomonari, Tetsu, Hirata, Misato, Bando, Masahiro, Kida, Yoshifumi, Tanaka, Takahiro, Kawaguchi, Tomoyuki, Wada, Hironori, Taniguchi, Tatsuya, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Tanahashi, Toshihito, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508441/
https://www.ncbi.nlm.nih.gov/pubmed/34638401
http://dx.doi.org/10.3390/cancers13194917
_version_ 1784582098196103168
author Hirao, Akihiro
Sato, Yasushi
Tanaka, Hironori
Nishida, Kensei
Tomonari, Tetsu
Hirata, Misato
Bando, Masahiro
Kida, Yoshifumi
Tanaka, Takahiro
Kawaguchi, Tomoyuki
Wada, Hironori
Taniguchi, Tatsuya
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Tanahashi, Toshihito
Takayama, Tetsuji
author_facet Hirao, Akihiro
Sato, Yasushi
Tanaka, Hironori
Nishida, Kensei
Tomonari, Tetsu
Hirata, Misato
Bando, Masahiro
Kida, Yoshifumi
Tanaka, Takahiro
Kawaguchi, Tomoyuki
Wada, Hironori
Taniguchi, Tatsuya
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Tanahashi, Toshihito
Takayama, Tetsuji
author_sort Hirao, Akihiro
collection PubMed
description SIMPLE SUMMARY: The mechanism of resistance to multikinase inhibitors in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the responsible miRNAs and target genes involved in the mechanism of resistance. Four miRNAs were significantly upregulated. Among them, we found that miR-125-5p induced sorafenib resistance in HCC cells and in a mouse model. We also revealed that miR-125-5p suppressed ataxin-1 as a target gene and consequently induced Snail-mediated epithelial-mesenchymal transition (EMT) and cancer stemness. Moreover, we demonstrated that ataxin-1 expression has an impact on the prognosis of patients with HCCs. In the future, by comparing the expression status of miR-125b-5p/ataxin-1 and the effect of sorafenib in the clinical setting, it is expected that miR-125b-5p will be established as an effective drug selection marker for treatment selection in patients with HCC. ABSTRACT: The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression—findings similar to those for PLC/PRF5-R2—which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients.
format Online
Article
Text
id pubmed-8508441
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85084412021-10-13 MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Hirao, Akihiro Sato, Yasushi Tanaka, Hironori Nishida, Kensei Tomonari, Tetsu Hirata, Misato Bando, Masahiro Kida, Yoshifumi Tanaka, Takahiro Kawaguchi, Tomoyuki Wada, Hironori Taniguchi, Tatsuya Okamoto, Koichi Miyamoto, Hiroshi Muguruma, Naoki Tanahashi, Toshihito Takayama, Tetsuji Cancers (Basel) Article SIMPLE SUMMARY: The mechanism of resistance to multikinase inhibitors in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the responsible miRNAs and target genes involved in the mechanism of resistance. Four miRNAs were significantly upregulated. Among them, we found that miR-125-5p induced sorafenib resistance in HCC cells and in a mouse model. We also revealed that miR-125-5p suppressed ataxin-1 as a target gene and consequently induced Snail-mediated epithelial-mesenchymal transition (EMT) and cancer stemness. Moreover, we demonstrated that ataxin-1 expression has an impact on the prognosis of patients with HCCs. In the future, by comparing the expression status of miR-125b-5p/ataxin-1 and the effect of sorafenib in the clinical setting, it is expected that miR-125b-5p will be established as an effective drug selection marker for treatment selection in patients with HCC. ABSTRACT: The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression—findings similar to those for PLC/PRF5-R2—which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients. MDPI 2021-09-30 /pmc/articles/PMC8508441/ /pubmed/34638401 http://dx.doi.org/10.3390/cancers13194917 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hirao, Akihiro
Sato, Yasushi
Tanaka, Hironori
Nishida, Kensei
Tomonari, Tetsu
Hirata, Misato
Bando, Masahiro
Kida, Yoshifumi
Tanaka, Takahiro
Kawaguchi, Tomoyuki
Wada, Hironori
Taniguchi, Tatsuya
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Tanahashi, Toshihito
Takayama, Tetsuji
MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title_full MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title_fullStr MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title_full_unstemmed MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title_short MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
title_sort mir-125b-5p is involved in sorafenib resistance through ataxin-1-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508441/
https://www.ncbi.nlm.nih.gov/pubmed/34638401
http://dx.doi.org/10.3390/cancers13194917
work_keys_str_mv AT hiraoakihiro mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT satoyasushi mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT tanakahironori mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT nishidakensei mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT tomonaritetsu mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT hiratamisato mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT bandomasahiro mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT kidayoshifumi mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT tanakatakahiro mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT kawaguchitomoyuki mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT wadahironori mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT taniguchitatsuya mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT okamotokoichi mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT miyamotohiroshi mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT mugurumanaoki mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT tanahashitoshihito mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma
AT takayamatetsuji mir125b5pisinvolvedinsorafenibresistancethroughataxin1mediatedepithelialmesenchymaltransitioninhepatocellularcarcinoma